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Abstract
Background  and  objective: The  aim  of  this  randomized,  prospective  and  double  blinded  study
is to  investigate  effects  of  different  esmolol  use  on  hemodynamic  response  of  laryngoscopy,
endotracheal  intubation  and  sternotomy  in  coronary  artery  bypass  graft  surgery.
Methods: After  approval  of  local  ethics  committee  and  patients’  written  informed  consent,  45
patients  were  randomized  into  three  groups  equally.  In  Infusion  Group;  from  10  min  before  intu-
bation  up  to  5th  minute  after  sternotomy,  0.5  mg/kg/min  esmolol  infusion,  in  Bolus  Group;  2  min
before  intubation  and  sternotomy  1.5  mg/kg  esmolol  IV  bolus  and  in  Control  Group;  %0.9  NaCl
was  administered.  All  demographic  parameters  were  recorded.  Heart  rate  and  blood  pressure
were  recorded  before  infusion  up  to  anesthesia  induction  in  every  minute,  during  endotracheal
intubation,  every  minute  for  10  minutes  after  endotracheal  intubation  and  before,  during  and
after  sternotomy  at  ﬁrst  and  ﬁfth  minutes.
Results:  While  area  under  curve  (AUC)  (SAP  ×  time)  was  being  found  more  in  Group  B  and  C
than Group  I,  AUC  (SAP  ×  Tint and  Tst)  and  AUC  (SAP  ×  T2)  was  found  more  in  Group  B  and  C
than Group  I  (p  <  0.05).  Moreover  AUC  (HR  ×  Tst)  was  found  less  in  Group  B  than  Group  C  but  no
signiﬁcant  difference  was  found  between  Group  B  and  Group  I.
Conclusion: This  study  highlights  that  esmolol  infusion  is  more  effective  than  esmolol  bolus
administration on  controlling  systolic  arterial  pressure  during  endotracheal  intubation  and
sternotomy  in  CABG  surgery.
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Comparac¸ão  de  esmolol  em  bolus  e  infusão  contínua  na  resposta  hemodinâmica  à
laringoscopia,  intubac¸ão  orotraqueal  e  esternotomia  em  cirurgia  de  revascularizac¸ão
coronária
Resumo
Justiﬁcativa  e  objetivo: o  objetivo  deste  estudo  prospectivo,  randômico  e  duplo-cego  foi
investigar os  efeitos  do  uso  diferente  de  esmolol  na  resposta  hemodinâmica  à  laringoscopia,
intubac¸ão orotraqueal  e  esternotomia  em  cirurgia  de  revascularizac¸ão  coronária.
Métodos: após  obter  a  aprovac¸ão  do  Comitê  de  Ética  local  e  consentimento  informado  assi-
nado pelos  pacientes,  45  pacientes  foram  randomicamente  divididos  em  três  grupos.  O  Grupo  I
(infusão)  recebeu  0,5  mg/kg/min  de  esmolol  em  infusão  a  partir  de  10  min  antes  da  intubac¸ão
até 5  minutos  após  a  esternotomia;  o  Brupo  B  (bolus)  recebeu  1,5  mg/kg  de  esmolol  em  bolus
IV  a  partir  de  2  min  antes  da  intubac¸ão  e  esternotomia;  o  grupo  C  (controle)  recebeu  NaCl  a
0,9%.  Todos  os  parâmetros  demográﬁcos  foram  registados.  Os  valores  de  frequência  cardíaca
e  pressão  arterial  foram  registrados  desde  antes  da  infusão  até  a  induc¸ão  da  anestesia  a  cada
minuto,  durante  a  intubac¸ão  endotraqueal,  a  cada  minuto  durante  10  min  após  a  intubac¸ão
endotraqueal e  antes,  durante  e  após  a  esternotomia  no  primeiro  e  quinto  minutos.
Resultados: enquanto  a  área  sob  a  curva  (ASC)  (SAP  ×  tempo)  foi  maior  nos  grupos  B  e  C  que  no
Grupo I,  a  ASC  (SAP  ×  Tint e  Tst)  e  ASC  (SAP  ×  T2)  foram  maiores  nos  grupos  B  e  C  que  no  Grupo
I (p  <  0,05).  Além  disso,  a  ASC  (FC  ×  Tst))  foi  menor  no  Grupo  B  que  no  Grupo  C,  mas  não  houve
diferenc¸a signiﬁcante  entre  os  grupos  B  e  I.
Conclusão:  este  estudo  destaca  que  a  administrac¸ão  de  esmolol  em  infusão  é  mais  eﬁcaz
que em  bolus  para  controlar  a  pressão  arterial  sistólica  durante  a  intubac¸ão  endotraqueal  e
esternotomia  em  CRC.
© 2013  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  
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atients  undergoing  coronary  artery  bypass  graft  (CABG)
urgery are  at  risk  for  perioperative  myocardial  ischemia.
achycardia as  a  predictor  for  increased  myocardial  oxygen
onsumption which  doubles  the  incidence  of  myocardial
schemia. During  the  operative  procedure  for  coronary
evascularization, some  maneuvers,  such  as  intubation,
ternotomy and  mediastinal  preparation,  may  be  associated
ith tachycardia  and  increases  in  blood  pressure  despite  the
dequate level  of  anesthesia.1
Some  drugs  (IV  opioids,  vasodilators,  calcium  channel
nd -blockers)  are  available  for  the  clinicians  to  control
he hemodynamic  response  to  laryngoscopy  and  intubation.2
-adrenoceptor  blockers  were  shown  to  decrease  the  inci-
ence of  postoperative  myocardial  ischemia.3
Esmolol  (metil-3[4-(2-hidroxy-3[izopropylamino]propxy)
enyl]  is  a  speciﬁc  cardioselective  beta  1-blocker  and  it
s hydrosoluble,  without  intrinsic  sympathetic  activity  or
embrane stabilizing  activity  at  therapeutic  dosages.  Distri-
ution and  elimination  half-life  is  2  and  9  min,  respectively.
smolol is  hydrolyzed  by  the  blood  esterases  and  a  suitable
gent for  the  perioperative  period.4
Esmolol  as  a  bolus  or  infusion  was  shown  to  prevent  tachy-
ardia and  hypertension  during  laryngoscopy  and  intubation
n a  meta-analysis  and  previous  studies.5--7
So  far,  esmolol  bolus  and  infusion  administration  has  not
een previously  compared  in  cardiac  patients.  The  pur-
ose of  this  randomized,  prospective,  double  blinded  study,
as to  evaluate  the  effect  of  1.5  mg/kg  esmolol  bolus  and
.5 mg/kg/min  esmolol  infusion  on  hemodynamic  response
I
t
l
sf  laryngoscopy,  endotracheal  intubation  and  sternotomy  in
oronary artery  bypass  graft  (CABG)  surgery.
ethods
orty  ﬁve  patients,  aging  between  18  and  80  years,  ejection
raction >40%,  in  ASA  II--IV  status,  scheduled  for  elec-
ive CABG  surgery,  between  February  and  April  2006,  in
nkara University  Medical  Faculty  were  enrolled  to  the
tudy after  obtaining  approval  from  the  Local  Research
thics Committee  and  written  informed  consent.  Patients
ith asthma,  ﬁrst-degree  atrioventricular  block,  heart  rate
50 beats/min,  acute  myocardial  infarction,  Mallampati
core more  than  two  and  under  -blocker  treatment  or  con-
raindicated for  -blocker  agent  were  excluded  from  the
tudy.
One hour  before  the  operation,  patients  were  pre-
edicated with  2.5  mg  diazepam  and  50  mg  dolantine  IM.
reoperative medical  treatments  were  continued  till  the
orning of  the  operation.  Patients’  age,  gender,  weight,
eight, chronic  diseases  and  medications  were  recorded  as
emographic parameters.  Upon  their  arrival  to  the  oper-
ting room  patients  were  monitored  by  pulse  oximetry,
lectrocardiogram  and  non-invasive  arterial  blood  pressure.
n intravenous  line  was  inserted  with  18  gauge  catheter
nd %  0.9  NaCl  infusion  was  started,  0.04  mg/kg  midazolam
V was  administered.  For  invasive  blood  pressure  moni-
orization, an  intraarterial  catheter  was  inserted  into  the
eft radial  artery  after  local  anesthetic  inﬁltration.  Sixty
econds after  induction  of  general  anesthesia  with  0.3  mg/kg
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aEsmolol  use  on  hemodynamic  response  
ethomidate,  5  g/kg  fentanyl  vs.  0.1  mg/kg  vecuronium
patients were  intubated  by  the  same  clinician  who  were
blind to  the  study  drugs.  Anesthesia  was  maintained  with
3 g/kg  fentanyl  and  0.01  mg/kg  midazolam  IV  bolus  injec-
tion every  30  min.  Patients  were  ventilated  to  normocapnie
with 50%  air-oxygen  in  approximately  0.5  MAC  isoﬂurane.
0.03 mg/kg  vecuronium  IV  was  administered  as  needed.
Patients were  randomly  assigned  according  to  computer-
generated random  number  sequence  into  one  of  three
groups. In  Infusion  Group  (Group  I);  0.5  mg/kg/min  esmolol
infusion was  started  10  min  before  the  endotracheal  intuba-
tion up  to  5th  minute  after  sternotomy,  and  2  min  before
both intubation  and  sternotomy  %0.9  NaCl  was  admin-
istered, in  Bolus  Group  (Group  B);  2  min  before  both
endotracheal intubation  and  sternotomy  1.5  mg/kg  esmolol
bolus IV  and  from  10  min  before  endotracheal  intubation
up to  5th  minute  after  sternotomy  %0.9  NaCl  was  adminis-
tered and  in  Control  Group  (Group  C);  %0.9  NaCl  infusion  and
bolus was  administered  instead  of  esmolol.  Heart  rate  (HR)
and systolic  arterial  pressure  (SAP),  diastolic  arterial  pres-
sure (DAP)  and  mean  arterial  pressure  (MAP)  were  recorded
before infusion  (baseline)  up  to  anesthesia  induction,  dur-
ing and  soon  after  anesthesia  induction,  during  endotracheal
intubation„ every  minute  for  10  min  after  endotracheal  intu-
bation and  before,  during  and  at  ﬁrst  and  ﬁfth  minutes  after
sternotomy. All  demographic  parameters  were  recorded.
SPSS  10.0  for  Windows  (SPSS  Inc,  Chicago,  IL,  USA)  was
used for  all  data  analyses.  For  ˛  =  0.05  and  ˇ  =  0.20,  sam-
ple size  was  calculated  15  subjects  for  each  groups.  ANOVA
and Chi-square  tests  were  used  for  analysis  of  demographic
variables. Area  under  curve  (AUC)  (heart  rate,  systolic,  dia-
stolic and  mean  arterial  pressure  x  time)  was  calculated  and
compared with  one-way  ANOVA  test  between  groups.  A  p
value of  <0.05  was  considered  statistically  signiﬁcant.
Results
No  signiﬁcant  difference  was  found  between  groups  accord-
ing to  demographic  parameters  (Table  1).
AUC  (heart  rate,  systolic,  diastolic  and  mean  arte-
rial pressure  ×  time)  between  groups  were  compared  and
according to  Table  2,  Group  I  was  signiﬁcantly  more  effective
than other  two  groups  in  controlling  systolic  arterial  pressure
(SAP) but  no  signiﬁcant  difference  on  other  parameters  was
found.
AUC (heart  rate,  systolic,  diastolic  and  mean  arterial
pressure ×  T1 (time  between  the  beginning  of  infusion  and
the beginning  of  anesthesia  induction)  and  T2 (time  between
the beginning  of  anesthesia  induction  and  the  5th  minute
after sternotomy))  were  compared.  According  to  Table  3
infusion group  was  signiﬁcantly  more  effective  than  other
two groups  in  controlling  SAP  after  induction  but  no  signiﬁ-
cant difference  was  observed  on  other  parameters.
AUC  (heart  rate,  systolic,  diastolic  and  mean  arterial
pressure ×  Tint (time  from  endotracheal  intubation  to  ster-
notomy) and  Tst (time  from  beginning  of  sternotomy  to  5th
min after  sternotomy)  were  compared.  According  to  Table
4, infusion  group  was  signiﬁcantly  more  effective  than  other
two groups  on  controlling  SAP  during  sternotomy  and  intuba-
tion. Moreover  bolus  group  was  signiﬁcantly  more  effective
than control  group  in  controlling  heart  rate  (HR)  during  ster-
m
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otomy  but  no  signiﬁcant  difference  was  observed  between
nfusion and  bolus  group.
No  adverse  or  side  effects  were  recorded  in  both  groups.
iscussion
his  prospective,  randomized,  double  blinded  trial  was
esigned to  determine  the  hemodynamic  effects  of  different
se of  esmolol  during  laryngoscopy,  intubation  and  ster-
otomy in  CABG  surgeries  and  as  a result  of  this  study  we
ound out  that  while  esmolol  infusion  was  signiﬁcantly  more
ffective than  esmolol  bolus  on  controlling  SAP  during  both
ntubation and  sternotomy,  esmolol  bolus  was  signiﬁcantly
ore effective  on  controlling  HR  only  during  sternotomy
hen compared  to  control  group  but  no  signiﬁcant  dif-
erence was  found  when  compared  to  infusion  group.  No
igniﬁcant side  effects  were  observed.
Cardiovascular  changes  such  as  hypertension  and  tachy-
ardia during  tracheal  intubation  are  potentially  detrimen-
al to  patients  with  ischemic  heart  disease.  Esmolol  is  the
-selective adrenergic  blocker  available  and  with  its  rapid
nset and  extremely  short  duration  of  action,  would  appear
o be  an  ideal  drug  for  preventing  acute  increases  in  HR  and
AP.8
However,  we  would  advise  caution  when  using  bolus
nd infusion  doses  of  esmolol  but  no  patient  in  our  study
equired treatment  for  hypotension,  bradycardia,  or  signiﬁ-
ant arrhythmias.  No  side  effects  were  observed  in  any  group
f  patients.
Since esmolol  has  been  used  clinically,  its  infusion  use
efore CABG  surgery  or  other  procedures  for  preventing  car-
iac ischemia  was  studied  and  shown  to  be  effective.9 As
linical use  of  esmolol  became  more  common,  due  to  its
hort acting,  simple  and  effective  bolus  use  of  esmolol  had
ncreased.10--14
According  to  our  knowledge,  the  bolus  and  infusion
dministration of  esmolol  has  not  been  compared  before  in
 previous  study,  so  we  decided  to  design  this  study.
As  an  optimal  intravenous  (IV)  esmolol  dose  for  use  dur-
ng anesthesia  induction  (laryngoscopy  and  intubation)  and
mergence (extubation)  has  been  previously  determined  to
e 1.5  mg/kg,  we  used  the  same  bolus  dose  in  our  study.15--16
s  we  could  not  ﬁnd  an  optimal  infusion  dose  of  esmolol  we
sed an  average  infusion  dose  that  was  0.5  mg/kg/min  in
ur study.17 While  Parnass  et  al.13 were  found  no  difference
etween 100  and  200  mg  esmolol  on  controlling  hemody-
amic response  during  intubation,  Yuan  et  al.12 found  out
hat 200  mg  esmolol  presented  a  better  hemodynamic  sta-
ility than  100  mg  esmolol  during  induction  of  anesthesia  in
heir study.  Moreover,  in  another  multicenter  study,  while  IV
olus administration  of  100  mg  esmolol  was  being  shown  to
e effective  in  controlling  hemodynamic  response  of  endo-
racheal intubation,  200  mg  dosage  was  shown  to  cause  more
ypotension without  desired  effect.18
These  controversial  results  indicated  that  other  factors
uch as  patients’  medications,  other  diseases,  ASA  status,
ges, intubation  difﬁculties,  different  Mallampati  scores
ight have  affected  the  results  and  it  is  very  important  to
tandardize the  patients’  characteristics  with  even  the  clin-
cians who  attempt  to  intubate.  That  is  why  in  our  study,
atients were  intubated  by  the  same  clinician  who  was
250  E.M.  Efe  et  al.
Table  1  Demographic  data  of  groups.
Group  I  (n  =  15)  Group  B  (n  =  15)  Group  C  (n  =  15)  p
Age  (years) 61 ±  6 63 ±  7  64  ±  7  NS
Gender (M/F)  10/5  11/4  10/5  NS
Weight (kg)  84  ±  12  87  ±  10  81  ±  15  NS
Height (cm)  171  ±  6  175  ±  8  172  ±  9  NS
ASA Classiﬁcation  (I/II/III/IV)  0/1/14/0  0/2/13/0  0/3/12/0  NS
Chronic Disease  (±)  15/0  15/0  15/0  NS
Medication (±)  15/0  15/0  15/0  NS
Data is presented as mean ± SD.
Group  I: Esmolol infusion group Group B: Esmolol bolus group Group C: Control group; NS: Statistically not signiﬁcant.
Table  2  Area  under  curve  (AUC)  of  groups.  (HR,  SAP,  DAP  and  MAP  ×  T).
Group  I  (n  =  15)  Group  B  (n  =  15)  Group  C  (n  =  15)
HRXTIME  (cm2)  1729  ±  208  1893  ±  304  1973  ±  304
SAPXTIME(cm2)  2843  ±  360* 3297  ±  548  3151  ±  397
DAPXTIME(cm2)  1635  ±  364  1767  ±  348  1650  ±  304
MAPXTIME(cm2)  2189  ±  366  2404  ±  399  2225  ±  293
Data is presented as mean ± SD.
HR,  heart rate; SAP, systolic arterial pressure; DAP, diastolic arterial pressure; MAP, mean arterial pressure; T, time; Group I, Esmolol
infusion group; Group B, Esmolol bolus group Group C, control group.
* p < 0.05 compared with Group B and C.
Table  3  Area  under  curve  (AUC)  of  groups.  (HR,  SAP,  DAP  and  MAP  ×  T1 and  T2).
Group  I  (n  =  15)  Group  B  (n  =  15)  Group  C  (n  =  15)
HRxT1 (cm2)  743  ±  91  861  ±  167  835  ±  153
HRxT2 (cm2)  986  ±  136  1032  ±  150  1136  ±  224
SAPxT1 (cm2)  1329  ±  215  1456  ±  298  1408  ±  252
SAPxT2 (cm2)  1514  ±  193* 1840  ±  299  1743  ±  224
DAPxT1 (cm2)  661  ±  143  706  ±  161  669  ±  113
DAPxT2 (cm2)  973  ±  275  1061  ±  223  981  ±  211
MAPxT1 (cm2)  989  ±  161  1070  ±  199  973  ±  146
MAPxT2 (cm2)  1200  ±  265  1334  ±  259  1251  ±  191
Data is presented as mean ± SD.
HR,  heart rate; SAP, systolic arterial pressure; DAP, diastolic arterial pressure; MAP, mean arterial pressure; T1, time between the
beginning of infusion and the beginning of anesthesia induction; T2, time between the beginning of anesthesia induction and the 5th
minute after sternotomy; Group I, Esmolol infusion group; Group B, Esmolol bolus group; Group C, Control group.
* p < 0.05 compared with Group B and C.
Table  4  AUC  (HR,  SAP,  DAP  and  MAP  ×  Tint and  Tst)  of  groups.
Group  I  (n  =  15)  Group  B  (n  =  15)  Group  C  (n  =  15)
HR  ×  Tint (cm2)  797  ±  114  853  ±  135  925  ±  189
HR ×  Tst (cm2)  188  ±  29  179  ±  33** 212  ±  40
SAP ×  Tint (cm2)  1218  ±  157* 1486  ±  254  1368  ±  185
SAP ×  Tst (cm2)  296  ±  51* 354  ±  67  374  ±  60
DAP ×  Tint (cm2)  726  ±  103  857  ±  192  777  ±  170
DAP ×  Tst (cm2)  246  ±  207  203  ±  45  203  ±  50
MAP ×  Tint (cm2)  968  ±  249  1078  ±  222  981  ±  154
MAP ×  Tst (cm2)  231  ±  33  255  ±  52  169  ±  51
Data is presented as mean ± SD.
HR,  heart rate; SAP, systolic arterial pressure; DAP, diastolic arterial pressure; MAP, mean arterial pressure; TI˙nt, time from endotracheal
intubation to sternotomy; Tst, time from beginning of sternotomy to 5th minute after sternotomy; Group I, Esmolol infusion group; Group
B, Esmolol bolus group; Group C, control group.
* p < 0.05 compared with Group B and C.
** p < 0.05 compared with Group C.
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1Esmolol  use  on  hemodynamic  response  
blind  to  the  study  drug,  to  standardize  the  noxious  stim-
uli during  laryngoscopy  and  intubation.  Moreover  patients’
medications and  Mallampati  scores  were  similar  between
groups.
In some  previous  studies  patients  were  included  into  the
study according  to  their  medications  with  or  without  -
blocker agents.17,19 The  results  of  these  studies  revealed
that patients  who  enrolled  to  the  these  studies  should  have
been chosen  upon  their  treatment  of  -blocker  agents.  In
our study  the  patients  on  -blocker  agents  were  not  included
as similar  to  Korenaga  et  al’s  study.  They  excluded  patients
on -blocker  therapy  from  their  study  and  reported  a slight
but statistically  insigniﬁcant  decrease  in  heart  rate  from  83
to 70  beat/min  during  infusion  of  esmolol  500  g/kg/min
prior to  anesthetic  induction.17 The  same  dose  was  used
in our  study  and  we  also  did  not  observe  any  signiﬁcant
decrease in  HR.
But unlike  our  study,  Brujin  et  al19 investigated  the  hemo-
dynamic effects  of  esmolol  in  chronically  -blocked  patients
undergoing coronary  artery  bypass  surgery  and  they  con-
cluded that  in  patients  whom  chronic  -blocker  therapy  was
continued until  the  time  of  surgery,  esmolol  did  not  further
attenuated the  heart  rate  response  but  did  attenuated  the
increase in  blood  pressure.
There  are  different  doses  of  esmolol  studied  in  previous
studies and  the  choice  of  optimal  dose  of  esmolol  is  very
important to  balance  between  the  desired  and  side  effects.
Although we  preferred  1.5  mg/kg  bolus  dose  of  esmolol
and many  studies  showed  the  effectiveness  of  large  doses
of esmolol,  Bensky  et  al.20 compared  0.2  and  0.4  mg/kg
esmolol and  found  out  that  both  doses  were  more  effec-
tive in  decreasing  the  heart  rate  than  control  group  and  the
0.4 mg/kg  dose  signiﬁcantly  blunted  the  increase  in  mean
arterial pressure  seen  in  control  group.
However,  in  another  study,21 the  result  of  a  combina-
tion of  nicardipine  (30  g/kg)  and  esmolol  (1  mg/kg)  showed
no signiﬁcant  change  in  hemodynamic  response  to  tracheal
intubation when  compared  to  saline.
There  are  also  different  techniques  to  ﬁnd  out  the  best
one in  previous  studies.  Some  clinicians  investigated  the
effect of  esmolol  bolus  followed  by  esmolol  infusion  on
hemodynamic effects  to  ﬁnd  out  the  most  proper  dose  of
esmolol.11,22--26 In  a  study  made  by  Schäffer  et  al.,  double
bolus of  esmolol  was  used  instead  of  one  bolus  to  control
the hemodynamic  effect  and  they  reached  a  better  result
with double  bolus  of  100  mg  esmolol.27 In  another  previous
studies,28--37 esmolol  was  compared  with  other  agents  alone
or as  combination.
These techniques  and  different  doses  of  esmolol  should
be studied  to  use  alone  or  in  combination  to  ﬁnd  out  the  most
appropriate one.  However,  it  should  be  kept  in  mind  that  the
patient characteristics  and  different  procedures  may  affect
the effects  of  Esmolol  and  other  drugs.
There  are  some  limitations  of  this  current  study.  We  did
not calculate  PCWP  and  cardiac  index  in  our  study.  Those
parameters would  be  a  better  guide  for  cardiac  perfor-
mance. We  did  not  measure  catecholamine  levels  of  patients
which would  take  us  to  more  reliable  results  about  the  hemo-
dynamic and  stress  response.  Moreover  the  sample  size  of
the study  disabled  us  to  demonstrate  other  factors  that
might enroll  to  the  changes  for  hemodynamic  parameters.
As bolus  dose  was  not  as  effective  as  on  blood  pressure,  it
1251
ight  have  been  better  to  add  another  bolus  dose  group  or
ake double  boluses  to  investigate  the  effectiveness  as  the
revious studies.
In conclusion,  according  to  our  study  that  the  effect  of
smolol bolus  and  infusion  administration  on  hemodynamic
esponse to  laryngoscopy,  endotracheal  intubation  and  ster-
otomy in  CABG  surgery  was  compared,  both  groups  were
ound safe  and  esmolol  infusion  was  found  more  effective
han esmolol  bolus  on  controlling  SAP  during  both  intubation
nd sternotomy.
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